Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-021791
Filing Date
2025-08-14
Accepted
2025-08-14 13:40:44
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 46951
  Complete submission text file 0001415889-25-021791.txt   48695
Mailing Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304
Business Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Subject) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94231 | Film No.: 251217123
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)